drugset
drugset / Trial / NCT05532020

An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

NCT05532020 ↗

Phase 2 Unknown 30 enrolled Soleno Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 open-label, one-arm, clinical study to evaluate the efficacy and safety of DCCR (diazoxide choline) extended-release tablets over 1 year of treatment, in patients with genetic obesities.

Timeline

Start
2023-01
Primary completion
2024-01
Completion
2024-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazoxide Unknown 75 mg —
Subject Diazoxide Unknown 525 mg —

Indications

obesity due to SIM1 deficiency obesity due to prohormone convertase I deficiency severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency